1
|
Piasecki J, Škarabot J, Spillane P, Piasecki M, Ansdell P. Sex Differences in Neuromuscular Aging: The Role of Sex Hormones. Exerc Sport Sci Rev 2024; 52:54-62. [PMID: 38329342 DOI: 10.1249/jes.0000000000000335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2024]
Abstract
Males and females experience different trajectories of neuromuscular function across the lifespan, with females demonstrating accelerated deconditioning in later life. We hypothesize that the menopause is a critical period in the female lifespan, during which the dramatic reduction in sex hormone concentrations negatively impacts synaptic input to the motoneuron pool, as well as motor unit discharge properties.
Collapse
Affiliation(s)
- Jessica Piasecki
- Sport, Health and Performance Enhancement Research Centre, Nottingham Trent University, Nottingham, UK
| | - Jakob Škarabot
- School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK
| | - Padraig Spillane
- Department of Sport, Exercise and Rehabilitation, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK
| | - Mathew Piasecki
- Centre of Metabolism, Ageing and Physiology (COMAP), MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK
| | - Paul Ansdell
- Department of Sport, Exercise and Rehabilitation, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK
| |
Collapse
|
2
|
Madani P, Hesaraki S, Saeedifar M, Ahmadi Nasab N. The controlled release, bioactivity and osteogenic gene expression of Quercetin-loaded gelatin/tragacanth/ nano-hydroxyapatite bone tissue engineering scaffold. JOURNAL OF BIOMATERIALS SCIENCE. POLYMER EDITION 2023; 34:217-242. [PMID: 35960146 DOI: 10.1080/09205063.2022.2113293] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
In this study, a Gelatin/Tragacanth/Nano-hydroxyapatite scaffold was fabricated via freeze-drying method. A highly porous scaffold with an average pore diameter of 142 µm and porosity of 86% was found by the micro-computed tomography. The mean compressive strength of the scaffold was about 1.5 MPa, a value in the range of the spongy bone. The scaffold lost 10 wt.% of its initial weight after 28 days soaking in PBS that shows a fair degradation rate for a bone tissue engineering scaffold. Apatite formation ability of the scaffold was confirmed via scanning electron microscopy, X-ray diffraction and Fourier transforming infrared spectroscopy, after 28 days soaking in simulated body fluid. The scaffold was able to deliver 93% of the loaded drug, Quercetin, during 120 h in phosphate-buffered solution, in a sustainable manner. The MTT assay using human bone mesenchymal stem cells showed 84% cell viability of the Quercetin-loaded scaffold. The expression of the osteogenic genes including Col I, Runx-2, BGLAP (gene of osteocalcin), bFGF, SP7 (gene of osterix) and SPP1 (gene of osteopontin) were all upregulated when Quercetin was loaded on the scaffold, which indicates the synergetic effect of the drug and the scaffold.
Collapse
Affiliation(s)
- Parisa Madani
- Biomaterials Group, Department of Nanotechnology & Advanced Materials, Materials and Energy Research Center, Karaj, Iran
| | - Saeed Hesaraki
- Biomaterials Group, Department of Nanotechnology & Advanced Materials, Materials and Energy Research Center, Karaj, Iran
| | - Maryam Saeedifar
- Biomaterials Group, Department of Nanotechnology & Advanced Materials, Materials and Energy Research Center, Karaj, Iran
| | - Navid Ahmadi Nasab
- Department of Marine Biology, Faculty of Marine Science and Technology, University of Hormozgan, Bandar Abbas, Iran
| |
Collapse
|
3
|
The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density. Drugs 2021; 81:1831-1858. [PMID: 34724173 PMCID: PMC8578161 DOI: 10.1007/s40265-021-01625-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/11/2021] [Indexed: 12/26/2022]
Abstract
Osteoporosis is a highly prevalent bone disease affecting more than 37.5 million individuals in the European Union (EU) and the United States of America (USA). It is characterized by low bone mineral density (BMD), impaired bone quality, and loss of structural and biomechanical properties, resulting in reduced bone strength. An increase in morbidity and mortality is seen in patients with osteoporosis, caused by the approximately 3.5 million new osteoporotic fractures occurring every year in the EU. Currently, different medications are available for the treatment of osteoporosis, including anti-resorptive and osteoanabolic medications. Bisphosphonates, which belong to the anti-resorptive medications, are the standard treatment for osteoporosis based on their positive effects on bone, long-term experience, and low costs. However, not only medications used for the treatment of osteoporosis can affect bone: several other medications are suggested to have an effect on bone as well, especially on fracture risk and BMD. Knowledge about the positive and negative effects of different medications on both fracture risk and BMD is important, as it can contribute to an improvement in osteoporosis prevention and treatment in general, and, even more importantly, to the individual's health. In this review, we therefore discuss the effects of both osteoporotic and non-osteoporotic medications on fracture risk and BMD. In addition, we discuss the underlying mechanisms of action.
Collapse
|
4
|
Pouillès JM, Gosset A, Trémollieres F. [Menopause, menopause hormone therapy and osteoporosis. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]. GYNECOLOGIE, OBSTETRIQUE, FERTILITE & SENOLOGIE 2021; 49:420-437. [PMID: 33753297 DOI: 10.1016/j.gofs.2021.03.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Postmenopausal osteoporosis is a frequent clinical condition, which affects nearly 1 in 3 women. Estrogen deficiency leads to rapid bone loss, which is maximal within the first years after the menopause transition and can be prevented by menopause hormone therapy (MHT). Assessment of the individual risk of osteoporosis is primarily based on the measurement of bone mineral density (BMD) at the spine and femur by DXA. Clinical risk factors (CRFs) for fractures taken either alone or in combination in the FRAX score were shown not to reliably predict fractures and/or osteoporosis (as defined by a T-score<-2.5) in early postmenopausal women. If DXA measurement is indicated in all women with CRFs for fractures, it can be proposed on a case-by-case basis, when knowledge of BMD is likely to condition the management of women at the beginning of menopause, particularly the benefit-risk balance of MHT. MHT prevents both bone loss and degradation of the bone microarchitecture in early menopause. It significantly reduces the risk of fracture at all bone sites by 20 to 40% regardless of basal level of risk with an estrogen-dependent dose-effect. Given the inter-individual variability in bone response, individual monitoring of the bone effect of MHT is warranted when prescribed for the prevention of osteoporosis. This monitoring is based on repeated measurement of lumbar and femoral BMD (on the same DXA measurement system) after 2years of MHT, the response criterion being no significant bone loss. Discontinuation of treatment is associated with a resumption of transient bone loss although there is a large variability in the rate of bone loss among women. Basically, there is a return to the level of fracture risk comparable to that of in untreated woman of the same age within 2 to 5years. Therefore, when MHT is prescribed for the prevention of osteoporosis in women with an increased risk at the beginning of menopause, measurement of BMD is recommended when MHT is stopped in order to consider further management of the risk of fracture whenever necessary (with possibly another anti-osteoporotic treatment).
Collapse
Affiliation(s)
- J-M Pouillès
- Centre de ménopause et maladies osseuses métaboliques, hôpital Paule-de-Viguier, CHU Toulouse, 330, avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse, France
| | - A Gosset
- Centre de ménopause et maladies osseuses métaboliques, hôpital Paule-de-Viguier, CHU Toulouse, 330, avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse, France
| | - F Trémollieres
- Centre de ménopause et maladies osseuses métaboliques, hôpital Paule-de-Viguier, CHU Toulouse, 330, avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse, France; INSERM U1048, I2MC, équipe 9, université Toulouse III Paul-Sabatier, 1, avenue du Professeur-Jean-Poulhès, BP 84225, 31432 Toulouse cedex 4, France.
| |
Collapse
|
5
|
Lee SR, Cho MK, Cho YJ, Chun S, Hong SH, Hwang KR, Jeon GH, Joo JK, Kim SK, Lee DO, Lee DY, Lee ES, Song JY, Yi KW, Yun BH, Shin JH, Chae HD, Kim T. The 2020 Menopausal Hormone Therapy Guidelines. J Menopausal Med 2020; 26:69-98. [PMID: 32893509 PMCID: PMC7475284 DOI: 10.6118/jmm.20000] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Revised: 05/19/2020] [Accepted: 08/20/2020] [Indexed: 12/13/2022] Open
Affiliation(s)
| | - Sa Ra Lee
- Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Moon Kyoung Cho
- Department of Obstetrics and Gynecology, Chonnam National University Medical School, Gwangju, Korea
| | - Yeon Jean Cho
- Department of Obstetrics and Gynecology, Dong-A University Medical Center, Busan, Korea
| | - Sungwook Chun
- Department of Obstetrics and Gynecology, Inje University Haeundae Paik Hospital, Busan, Korea
| | - Seung Hwa Hong
- Department of Obstetrics and Gynecology, Chungbuk National University Hospital, Cheongju, Korea
| | - Kyu Ri Hwang
- Department of Obstetrics & Gynecology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea
| | - Gyun Ho Jeon
- Department of Obstetrics and Gynecology, Inje University Haeundae Paik Hospital, Busan, Korea
| | - Jong Kil Joo
- Department of Obstetrics and Gynecology, Pusan National University Hospital, Busan, Korea
| | - Seul Ki Kim
- Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea
| | - Dong Ock Lee
- Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea
| | - Dong Yun Lee
- Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Korea
| | - Eun Sil Lee
- Department of Obstetrics and Gynecology, Soonchunhyang University Seoul Hospital, Seoul, Korea
| | - Jae Yen Song
- Department of Obstetrics and Gynecology, The Catholic University of Korea College of Medicine, Seoul, Korea
| | - Kyong Wook Yi
- Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea
| | - Bo Hyon Yun
- Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea
| | - Jung Ho Shin
- Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea
| | - Hee Dong Chae
- Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
| | - Tak Kim
- Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea
| |
Collapse
|
6
|
Abstract
PURPOSE OF REVIEW The goal of the review is to assess the appropriateness of menopausal hormone therapy (MHT) for the primary prevention of bone loss in women at elevated risk in the early years after menopause. RECENT FINDINGS Estrogen alone or combined with progestin to protect the uterus from cancer significantly reduces the risk of osteoporosis-related fractures. MHT increases type 1 collagen production and osteoblast survival and maintains the equilibrium between bone resorption and bone formation by modulating osteoblast/osteocyte and T cell regulation of osteoclasts. Estrogens have positive effects on muscle and cartilage. Estrogen, but not antiresorptive therapies, can attenuate the inflammatory bone-microenvironment associated with estrogen deficiency. However, already on second year of administration, MHT is associated with excess breast cancer risk, increasing steadily with duration of use. MHT should be considered in women with premature estrogen deficiency and increased risk of bone loss and osteoporotic fractures. However, MHT use for the prevention of bone loss is hindered by increase in breast cancer risk even in women younger than 60 years old or who are within 10 years of menopause onset.
Collapse
Affiliation(s)
- Jan J Stepan
- Institute of Rheumatology, Prague, Czech Republic.
| | - Hana Hruskova
- Department of Obstetrics and Gynecology, First Faculty of Medicine, Prague, Czech Republic
- Charles University, Prague, Czech Republic
- General University Hospital in Prague, Prague, Czech Republic
| | - Miloslav Kverka
- Institute of Microbiology of the Czech Academy of Sciences, v.v.i., Prague, Czech Republic
- Institute of Experimental Medicine of the Czech Academy of Sciences, v.v.i., Prague, Czech Republic
| |
Collapse
|
7
|
Vignozzi L, Malavolta N, Villa P, Mangili G, Migliaccio S, Lello S. Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO. J Endocrinol Invest 2019; 42:609-618. [PMID: 30456623 DOI: 10.1007/s40618-018-0978-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2018] [Accepted: 11/04/2018] [Indexed: 01/04/2023]
Affiliation(s)
- L Vignozzi
- Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
| | - N Malavolta
- St Orsola-Malpighi Hospital, Cardio-Thoracic -Vascular Department, Program of Rheumatic and Connective Tissue Disordes and Bone Metabolic Diseases, Bologna, University of Bologna, Bologna, Italy
| | - P Villa
- Department of Obstetrics and Gynecology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy
| | - G Mangili
- Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital, Milan, Italy
| | - S Migliaccio
- Department of Movement, Human and Health Sciences, Unit of Endocrinology, University of "Foro Italico" of Rome, Largo Lauro De Bosis 6, 00195, Rome, Italy.
| | - S Lello
- Department of Woman and Child Health, Policlinico Gemelli Foundation, Rome, Italy
| |
Collapse
|
8
|
Kwon DH, Shin JH. Updated treatment guideline for hormone therapy in postmenopausal women. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION 2019. [DOI: 10.5124/jkma.2019.62.3.145] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Affiliation(s)
- Dae-Hui Kwon
- Department of Obstetrics and Gynecology, Guro Hospital, Korea University College of Medicine, Seoul, Korea
| | - Jung-Ho Shin
- Department of Obstetrics and Gynecology, Guro Hospital, Korea University College of Medicine, Seoul, Korea
| |
Collapse
|
9
|
McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 2017; 28:1723-1732. [PMID: 28144701 PMCID: PMC5391373 DOI: 10.1007/s00198-017-3919-1] [Citation(s) in RCA: 146] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2016] [Accepted: 01/09/2017] [Indexed: 11/28/2022]
Abstract
UNLABELLED Stopping denosumab after 8 years of continued treatment was associated with bone loss during a 1-year observation study in patients who were not prescribed osteoporosis treatment. Bone loss was attenuated in patients who began another osteoporosis therapy. Treatment to prevent bone loss upon stopping denosumab should be considered. INTRODUCTION This study aimed to understand osteoporosis management strategies during a 1-year observational follow-up after up to 8 years of denosumab treatment in a phase 2 study. METHODS During the observational year, patients received osteoporosis management at the discretion of their physician and returned to the clinic for BMD assessment and completion of an osteoporosis management questionnaire. Incidence of serious adverse events and fractures was collected. Analyses were descriptive. RESULTS Of 138 eligible patients, 82 enrolled in and completed the observation study. Most (65 [79%]) did not receive prescription osteoporosis medication, with "my doctor felt I no longer needed a medication" being the most common reason (23 [35%]). Of the 17 patients who took osteoporosis medications, 8 discontinued therapy during the observation study. In patients treated with denosumab for 8 years (N = 52), BMD decreased during the 1-year observation study (6.7% [lumbar spine], 6.6% [total hip]). Those who took osteoporosis medication during the observation study showed a smaller decline in BMD than those who did not. No new safety concerns were identified. Eight patients (9.8%), all of whom had at least one predisposing risk factor, experienced 17 fractures. This included seven patients who experienced one or more vertebral fractures. CONCLUSIONS Consistent with denosumab's mechanism of action, treatment cessation led to reversal of the drug's effect on BMD and perhaps fracture risk. For patients who took osteoporosis therapy, bone loss was attenuated. For patients at high fracture risk, switching to another osteoporosis therapy if denosumab is discontinued seems appropriate.
Collapse
Affiliation(s)
- M. R. McClung
- Oregon Osteoporosis Center, 2881 NW Cumberland Road, Portland, OR 97210 USA
- Australian Catholic University, Melbourne, Australia
| | | | - P. D. Miller
- Colorado Center for Bone Research, Lakewood, CO USA
| | - A. Wang
- Amgen Inc., Thousand Oaks, CA USA
| | - E. M. Lewiecki
- New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM USA
| |
Collapse
|
10
|
Kuh D, Muthuri S, Cooper R, Moore A, Mackinnon K, Cooper C, Adams JE, Hardy R, Ward KA. Menopause, Reproductive Life, Hormone Replacement Therapy, and Bone Phenotype at Age 60-64 Years: A British Birth Cohort. J Clin Endocrinol Metab 2016; 101:3827-3837. [PMID: 27472291 PMCID: PMC5052353 DOI: 10.1210/jc.2016-1828] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
CONTEXT Previous studies of menopausal age and length of reproductive life on bone are limited by retrospective reproductive histories, being cross-sectional, or lacking gold standard bone technologies or information on hormone replacement therapy (HRT) or surgical treatment. OBJECTIVE The objective of the study was to investigate age at menopause, length of reproductive life, and HRT use in relation to volumetric and areal bone mineral density (vBMD, aBMD), bone size, and strength in women aged 60-64 years. DESIGN This was a birth cohort study that followed up for 64 years with prospective measures of age at menarche and menopause and monthly HRT histories. SETTING The study was conducted in England, Scotland, and Wales. PARTICIPANTS Participants included 848 women with a known type of menopause and bone measures at 60-64 years. MAIN OUTCOME MEASURES Peripheral quantitative computed tomography measurements of the distal radius total and trabecular vBMD were measured. Diaphyseal radius total and medullary cross-sectional area, cortical vBMD, and polar strength strain index (SSI); dual-energy x-ray absorptiometry measurements of aBMD at the lumbar spine and total hip were also measured. RESULTS A 10-year increase in age at natural (but not surgical) menopause was associated with 8.2% (95% confidence interval [CI] 1.3%-15.1%, P = .02) greater trabecular vBMD and a 6.0% (95% CI 0.51%-11.5%, P = .03) greater total vBMD; findings were similar for length of reproductive life. A 10-year difference in HRT use was associated with a 6.0% (95% CI 2.6%-9.3%, P < .001) greater polar SSI and a 0.9% (95% CI 0.4%-1.5%, P = .001) greater cortical vBMD. These estimates changed little on adjustment. Estimates for aBMD were consistent with those for peripheral quantitative computed tomography. CONCLUSIONS The positive effects on trabecular vBMD of later natural menopause and longer reproductive life persisted into early old age. HRT use was associated with greater radius cortical vBMD and polar SSI and aBMD.
Collapse
Affiliation(s)
- D Kuh
- Medical Research Council Unit for Lifelong Health and Ageing (D.K., S.M., R.C., A.M., K.M., R.H.), University College London, London WC1B 5JU, United Kingdom; Medical Research Council Lifecourse Epidemiology Unit (C.C., K.A.W.), University of Southampton, Southampton SO16 6YD, United Kingdom; Clinical Radiology and Academic Health Science Centre (J.E.A.), Manchester Royal Infirmary, Central Manchester University Hospital, National Health Service Foundation Trust and University of Manchester, Manchester M13 9PT, United Kingdom; and Medical Research Council Human Nutrition Research (K.A.W.), Cambridge CB1 9NL, United Kingdom
| | - S Muthuri
- Medical Research Council Unit for Lifelong Health and Ageing (D.K., S.M., R.C., A.M., K.M., R.H.), University College London, London WC1B 5JU, United Kingdom; Medical Research Council Lifecourse Epidemiology Unit (C.C., K.A.W.), University of Southampton, Southampton SO16 6YD, United Kingdom; Clinical Radiology and Academic Health Science Centre (J.E.A.), Manchester Royal Infirmary, Central Manchester University Hospital, National Health Service Foundation Trust and University of Manchester, Manchester M13 9PT, United Kingdom; and Medical Research Council Human Nutrition Research (K.A.W.), Cambridge CB1 9NL, United Kingdom
| | - R Cooper
- Medical Research Council Unit for Lifelong Health and Ageing (D.K., S.M., R.C., A.M., K.M., R.H.), University College London, London WC1B 5JU, United Kingdom; Medical Research Council Lifecourse Epidemiology Unit (C.C., K.A.W.), University of Southampton, Southampton SO16 6YD, United Kingdom; Clinical Radiology and Academic Health Science Centre (J.E.A.), Manchester Royal Infirmary, Central Manchester University Hospital, National Health Service Foundation Trust and University of Manchester, Manchester M13 9PT, United Kingdom; and Medical Research Council Human Nutrition Research (K.A.W.), Cambridge CB1 9NL, United Kingdom
| | - A Moore
- Medical Research Council Unit for Lifelong Health and Ageing (D.K., S.M., R.C., A.M., K.M., R.H.), University College London, London WC1B 5JU, United Kingdom; Medical Research Council Lifecourse Epidemiology Unit (C.C., K.A.W.), University of Southampton, Southampton SO16 6YD, United Kingdom; Clinical Radiology and Academic Health Science Centre (J.E.A.), Manchester Royal Infirmary, Central Manchester University Hospital, National Health Service Foundation Trust and University of Manchester, Manchester M13 9PT, United Kingdom; and Medical Research Council Human Nutrition Research (K.A.W.), Cambridge CB1 9NL, United Kingdom
| | - K Mackinnon
- Medical Research Council Unit for Lifelong Health and Ageing (D.K., S.M., R.C., A.M., K.M., R.H.), University College London, London WC1B 5JU, United Kingdom; Medical Research Council Lifecourse Epidemiology Unit (C.C., K.A.W.), University of Southampton, Southampton SO16 6YD, United Kingdom; Clinical Radiology and Academic Health Science Centre (J.E.A.), Manchester Royal Infirmary, Central Manchester University Hospital, National Health Service Foundation Trust and University of Manchester, Manchester M13 9PT, United Kingdom; and Medical Research Council Human Nutrition Research (K.A.W.), Cambridge CB1 9NL, United Kingdom
| | - C Cooper
- Medical Research Council Unit for Lifelong Health and Ageing (D.K., S.M., R.C., A.M., K.M., R.H.), University College London, London WC1B 5JU, United Kingdom; Medical Research Council Lifecourse Epidemiology Unit (C.C., K.A.W.), University of Southampton, Southampton SO16 6YD, United Kingdom; Clinical Radiology and Academic Health Science Centre (J.E.A.), Manchester Royal Infirmary, Central Manchester University Hospital, National Health Service Foundation Trust and University of Manchester, Manchester M13 9PT, United Kingdom; and Medical Research Council Human Nutrition Research (K.A.W.), Cambridge CB1 9NL, United Kingdom
| | - J E Adams
- Medical Research Council Unit for Lifelong Health and Ageing (D.K., S.M., R.C., A.M., K.M., R.H.), University College London, London WC1B 5JU, United Kingdom; Medical Research Council Lifecourse Epidemiology Unit (C.C., K.A.W.), University of Southampton, Southampton SO16 6YD, United Kingdom; Clinical Radiology and Academic Health Science Centre (J.E.A.), Manchester Royal Infirmary, Central Manchester University Hospital, National Health Service Foundation Trust and University of Manchester, Manchester M13 9PT, United Kingdom; and Medical Research Council Human Nutrition Research (K.A.W.), Cambridge CB1 9NL, United Kingdom
| | - R Hardy
- Medical Research Council Unit for Lifelong Health and Ageing (D.K., S.M., R.C., A.M., K.M., R.H.), University College London, London WC1B 5JU, United Kingdom; Medical Research Council Lifecourse Epidemiology Unit (C.C., K.A.W.), University of Southampton, Southampton SO16 6YD, United Kingdom; Clinical Radiology and Academic Health Science Centre (J.E.A.), Manchester Royal Infirmary, Central Manchester University Hospital, National Health Service Foundation Trust and University of Manchester, Manchester M13 9PT, United Kingdom; and Medical Research Council Human Nutrition Research (K.A.W.), Cambridge CB1 9NL, United Kingdom
| | - K A Ward
- Medical Research Council Unit for Lifelong Health and Ageing (D.K., S.M., R.C., A.M., K.M., R.H.), University College London, London WC1B 5JU, United Kingdom; Medical Research Council Lifecourse Epidemiology Unit (C.C., K.A.W.), University of Southampton, Southampton SO16 6YD, United Kingdom; Clinical Radiology and Academic Health Science Centre (J.E.A.), Manchester Royal Infirmary, Central Manchester University Hospital, National Health Service Foundation Trust and University of Manchester, Manchester M13 9PT, United Kingdom; and Medical Research Council Human Nutrition Research (K.A.W.), Cambridge CB1 9NL, United Kingdom
| |
Collapse
|
11
|
Deal CL, Abelson AG. Management of osteoporosis. Rheumatology (Oxford) 2015. [DOI: 10.1016/b978-0-323-09138-1.00201-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
12
|
Schilling T, Ebert R, Raaijmakers N, Schütze N, Jakob F. Effects of phytoestrogens and other plant-derived compounds on mesenchymal stem cells, bone maintenance and regeneration. J Steroid Biochem Mol Biol 2014; 139:252-61. [PMID: 23262262 DOI: 10.1016/j.jsbmb.2012.12.006] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2012] [Revised: 12/06/2012] [Accepted: 12/10/2012] [Indexed: 01/13/2023]
Abstract
Phytoestrogens and other plant-derived compounds and extracts have been developed for the treatment of menopause-related complaints and disorders, e.g. hot flushes and osteoporosis. Since estrogens have been discussed to enhance the risk for hormone-sensitive cancers, research activities try to find alternatives. Phytoestrogens like genistein and resveratrol as well as other plant-derived compounds are capable of substituting for estrogens to some extent. Their effects on mesenchymal stem cells and the tissues derived therefrom have been investigated in vitro and in preclinical settings. Besides their well-known estrogenic, i.e. mainly antiresorptive effects on bone via estrogen receptor (ER) signalling, they also directly or indirectly affect osteogenic and adipogenic pathways. As a novel mechanism, phytoestrogens and plant-derived saponins and flavonoids like kaempferol and xanthohumol have been described to reciprocally affect the osteogenic versus the adipogenic differentiation pathway. Both, ER-mediated and other pathways mediate a shift towards osteogenesis by inhibiting PPARγ and C/EBPα, the key adipogenic transcription factors (TFs), while stimulating the key osteogenic TFs Runx2 and Sp7. Besides ER signalling, the broad spectrum of molecular mechanisms supporting osteogenesis comprises the modulation of PPARγ, Wnt/β-catenin, and Sirt1 signalling, which inversely influence the transcription or transactivation of osteogenic versus adipogenic TFs. Preventing the age- and hormone deficiency-related shift towards adipogenesis without provoking adverse estrogenic effects represents a very promising strategy for treating bone loss and other metabolic diseases beyond bone. Research on plant-derived compounds will have to be pursued in vitro as well as in preclinical studies and controlled clinical trials in humans are urgently needed. This article is part of a Special Issue entitled 'Phytoestrogens'.
Collapse
Affiliation(s)
- Tatjana Schilling
- University of Würzburg, Orthopaedic Department, Orthopaedic Centre for Musculoskeletal Research, Würzburg, Germany.
| | | | | | | | | |
Collapse
|
13
|
Brown JP, Roux C, Törring O, Ho PR, Beck Jensen JE, Gilchrist N, Recknor C, Austin M, Wang A, Grauer A, Wagman RB. Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res 2013; 28:746-52. [PMID: 23109251 PMCID: PMC3617467 DOI: 10.1002/jbmr.1808] [Citation(s) in RCA: 100] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2012] [Revised: 10/09/2012] [Accepted: 10/19/2012] [Indexed: 11/21/2022]
Abstract
Osteoporosis is a chronic disease and requires long-term treatment with pharmacologic therapy to ensure sustained antifracture benefit. Denosumab reduced the risk for new vertebral, nonvertebral, and hip fractures over 36 months in the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. Whereas discontinuation of denosumab has been associated with transient increases in bone remodeling and declines in bone mineral density (BMD), the effect on fracture risk during treatment cessation is not as well characterized. To understand the fracture incidence between treatment groups after cessation of investigational product, we evaluated subjects in FREEDOM who discontinued treatment after receiving two to five doses of denosumab or placebo, and continued study participation for ≥7 months. The off-treatment observation period for each individual subject began 7 months after the last dose and lasted until the end of the study. This subgroup of 797 subjects (470 placebo, 327 denosumab), who were evaluable during the off-treatment period, showed similar baseline characteristics for age, prevalent fracture, and lumbar spine and total hip BMD T-scores. During treatment, more placebo-treated subjects as compared with denosumab-treated subjects sustained a fracture and had significant decreases in BMD. During the off-treatment period (median 0.8 years per subject), 42% versus 28% of placebo- and denosumab-treated subjects, respectively, initiated other therapy. Following discontinuation, similar percentages of subjects in both groups sustained a new fracture (9% placebo, 7% denosumab), resulting in a fracture rate per 100 subject-years of 13.5 for placebo and 9.7 for denosumab (hazard ratio [HR] 0.82; 95% confidence interval [CI], 0.49-1.38), adjusted for age and total hip BMD T-score at baseline. There was no apparent difference in fracture occurrence pattern between the groups during the off-treatment period. In summary, there does not appear to be an excess in fracture risk after treatment cessation with denosumab compared with placebo during the off-treatment period for up to 24 months.
Collapse
Affiliation(s)
- Jacques P Brown
- Centre Hospitalier Universitaire de Québec-Centre Hospitalier de l'Université Laval (CHUQ-CHUL) Research Centre, Québec, Québec, Canada.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Giroux S, Bussières J, Bureau A, Rousseau F. UGT2B17 gene deletion associated with an increase in bone mineral density similar to the effect of hormone replacement in postmenopausal women. Osteoporos Int 2012; 23:1163-70. [PMID: 21614655 DOI: 10.1007/s00198-011-1662-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2010] [Accepted: 03/29/2011] [Indexed: 11/24/2022]
Abstract
UNLABELLED UGT2B17 is one of the most important enzymes for androgen metabolism. In addition, the UGT2B17 gene is one of the most commonly deleted regions of the human genome. The deletion was previously found associated with higher femoral bone density in men and women, and we replicated this association in a sample of postmenopausal who never used hormone therapy. INTRODUCTION Deletion of the UGT2B17 gene was previously shown to be associated with a higher hip bone mineral density (BMD). Using a PCR assay, we tried to replicate the association among a large group of 2,379 women. We examined the effect of the deletion on femoral neck BMD and lumbar spine BMD according to the menopausal status and hormone replacement therapy (HRT). METHODS We used a high-throughput PCR assay to identify the gene and the deletion in a population of well-characterized women. Two additional polymorphisms, UGT2B28 deletion and UGT2B15 rs1902023 G > T were also investigated. RESULTS Only UGT2B17 deletion was associated with LS and FN BMD. Furthermore, the association was seen only among postmenopausal women who had never used hormone replacement as in the first reported association. CONCLUSIONS We confirmed the association between UGT2B17 deletion and a higher LS and FN BMD. In addition, we show that the association is observed among postmenopausal women who never used HRT consistent with the enzymatic function of UGT2B17. The analysis shows that those having one or two UGT2B17 alleles benefit from HRT, which is not the case for null carriers.
Collapse
Affiliation(s)
- S Giroux
- Centre de Recherche de l'Hôpital St-François d'Assise du Centre hospitalier universitaire de Québec, 10 rue de l'Espinay, Québec G1L 3L5, Canada.
| | | | | | | |
Collapse
|
15
|
Engel P, Fabre A, Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Risk of osteoporotic fractures after discontinuation of menopausal hormone therapy: results from the E3N cohort. Am J Epidemiol 2011; 174:12-21. [PMID: 21555715 DOI: 10.1093/aje/kwr044] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
While current use of menopausal hormone therapy (MHT) reduces the risk of osteoporotic fractures, epidemiologic studies suggest that protection wears off rapidly after discontinuation of treatment. The authors identified 5,589 first osteoporotic fractures (2,235 major osteoporotic fractures) among 70,182 postmenopausal women from the French E3N cohort (1992-2008) and used Cox multivariate proportional hazards regression models to estimate hazard ratios. Persistence of protection against major osteoporotic fractures after MHT discontinuation was only observed when MHT had been used for at least 5 years, with a slightly more important decrease within the 5 years after discontinuation (compared with never use of MHT, hazard ratio = 0.68, 95% confidence interval: 0.50, 0.92) than beyond 5 years (hazard ratio = 0.83, 95% confidence interval: 0.69, 0.99); the P value for homogeneity between the 2 estimates was not significant. Oral estrogen use and transdermal estrogen use conveyed similar estimates in past users. Among current users, the authors confirmed a protective effect of MHT against risk of osteoporotic fractures. These findings, which relied on a number of MHT combinations, suggested that such therapies should be used for 5 years or more for reducing risk of fracture after treatment discontinuation.
Collapse
Affiliation(s)
- Pierre Engel
- INSERM, Centre for Research in Epidemiology and Population Health, Team 9, Nutrition, Hormones and Women’s Health Team, Institut Gustave Roussy, University Paris-Sud, UMRS 1018, Villejuif, France
| | | | | | | | | | | |
Collapse
|
16
|
Deal CL, Abelson AG. Management of osteoporosis. Rheumatology (Oxford) 2011. [DOI: 10.1016/b978-0-323-06551-1.00197-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
17
|
Rolnick SJ, Jackson JM, Amundson JH. Development, implementation and evaluation of an electronic medical record prompt for bone density testing. Health Informatics J 2010; 15:296-304. [PMID: 20007654 DOI: 10.1177/1460458209345900] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The purpose of this study was to assess whether an electronic prompt promoting BMD testing affected the proportion of patients who received BMD and/or bone health medication. Rheumatology providers of patients 40+, on prednisone, with no record of BMD testing in the past 2 years, were targeted with the message: 'This patient is at risk for osteoporosis due to prednisone use. We have no record of a recent Dexa scan.' We also surveyed providers on the prompt's value. The use of prednisone remained stable; BMD testing was quite low in all periods but increased slightly (non-statistically) over time, as did bone health medication use. Providers found the prompt not tailored enough to be clinically meaningful. Electronic prompts seem beneficial in theory; however, putting them into practice has challenges. While the EMR has great potential to improve care, more needs to be done to ensure optimal use.
Collapse
Affiliation(s)
- Sharon J Rolnick
- HealthPartners Research Foundation, Minneapolis, MN 55440-1524, USA.
| | | | | |
Collapse
|
18
|
Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17:25-54; quiz 55-6. [PMID: 20061894 DOI: 10.1097/gme.0b013e3181c617e6] [Citation(s) in RCA: 344] [Impact Index Per Article: 24.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
OBJECTIVE To update the evidence-based position statement published by The North American Menopause Society (NAMS) in 2006 regarding the management of osteoporosis in postmenopausal women. METHODS NAMS followed the general principles established for evidence-based guidelines to create this updated document. A panel of clinicians and researchers expert in the field of metabolic bone diseases and/or women's health was enlisted to review the 2006 NAMS position statement, compile supporting statements, and reach consensus on recommendations. The panel's recommendations were reviewed and approved by the NAMS Board of Trustees. RESULTS Osteoporosis, which is especially prevalent among older postmenopausal women, increases the risk of fractures. Hip and spine fractures are associated with particularly high morbidity and mortality in this population. Given the health implications of osteoporotic fractures, the primary goal of osteoporosis therapy is to prevent fractures, which is accomplished by slowing or stopping bone loss, maintaining bone strength, and minimizing or eliminating factors that may contribute to fractures. The evaluation of postmenopausal women for osteoporosis risk requires a medical history, physical examination, and diagnostic tests. Major risk factors for postmenopausal osteoporosis (as defined by bone mineral density) include advanced age, genetics, lifestyle factors (such as low calcium and vitamin D intake, smoking), thinness, and menopause status. The most common risk factors for osteoporotic fracture are advanced age, low bone mineral density, and previous fracture as an adult. Management focuses first on nonpharmacologic measures, such as a balanced diet, adequate calcium and vitamin D intake, adequate exercise, smoking cessation, avoidance of excessive alcohol intake, and fall prevention. If pharmacologic therapy is indicated, government-approved options are bisphosphonates, selective estrogen-receptor modulators, parathyroid hormone, estrogens, and calcitonin. CONCLUSIONS Management strategies for postmenopausal women involve identifying those at risk for fracture, followed by instituting measures that focus on reducing modifiable risk factors through dietary and lifestyle changes and, if indicated, pharmacologic therapy.
Collapse
|
19
|
López García-Franco A, Alonso Coello P, del Cura González I, Ojuel Solsona J, Arribas Mir L, Fuentes Pujol M, Bailón Muñoz E, Gutierrez Teira B, Iglesias Piñeiro MJ, Landa Goñi J. [Should we change our attitude on postmenopausal hormone replacement therapy?]. Aten Primaria 2009; 41:295-7. [PMID: 19481838 DOI: 10.1016/j.aprim.2009.03.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2009] [Accepted: 03/30/2009] [Indexed: 11/30/2022] Open
|
20
|
Koduganti RR, Gorthi C, Reddy PV, Sandeep N. Osteoporosis: "A risk factor for periodontitis". J Indian Soc Periodontol 2009; 13:90-6. [PMID: 20407657 PMCID: PMC2847131 DOI: 10.4103/0972-124x.55841] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2009] [Accepted: 05/22/2009] [Indexed: 01/05/2023] Open
Abstract
Aging is one of the major health challenges today. Most of the diseases related to aging, lead to significantly increased morbidity and mortality and higher public expenditure of funds. The interconnection between socio-economic conditions and social vulnerability is reflected in precarious states of health with prominence of high rates of osteoporosis and periodontal disease.Both these diseases have been highlighted in public health because of the impact caused by bone fracture and tooth loss. Thus, the elderly could help live a healthier and more meaningful life with the prevention of these diseases.
Collapse
Affiliation(s)
- Rekha Rani Koduganti
- Professor and H.O.D, Department of Periodontics, Panineeya Mahavidhyalaya Institute of Dental Sciences and Research, Kamala Nagar, Dilsukhnagar, Hyderabad - 500 060, India
| | - Chandana Gorthi
- Sr. Lecturer, Department of Periodontics, Panineeya Mahavidhyalaya Institute of Dental Sciences and Research, Kamala Nagar, Dilsukhnagar, Hyderabad - 500 060, India
| | - P. Veerendranath Reddy
- Sr. Lecturer, Department of Periodontics, Panineeya Mahavidhyalaya Institute of Dental Sciences and Research, Kamala Nagar, Dilsukhnagar, Hyderabad - 500 060, India
| | - N. Sandeep
- Reader, Department of Periodontics, Panineeya Mahavidhyalaya Institute of Dental Sciences and Research, Kamala Nagar, Dilsukhnagar, Hyderabad - 500 060, India
| |
Collapse
|
21
|
Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000-2005. Menopause 2009; 16:77-83. [PMID: 18703983 DOI: 10.1097/gme.0b013e31817b816e] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVE To determine the trend in incidence of fractures among perimenopausal and postmenopausal women during the periods immediately before and after publication of the Women's Health Initiative and Heart and Estrogen/Progestin Replacement Study (HERS) II data. DESIGN This was an ecological study using a claims database for multiple healthcare plans. The cohort of women aged 40 to 69 years was included. Diagnostic codes for fractures likely to be osteoporosis related and prescriptions for hormone therapy and other bone-modifying medications were identified. Annual incidence rates and trends in incidence over time for fractures and prescriptions were determined for the period 2000 through 2005. RESULTS Enrollment among women aged 40 to 69 years increased from 919,389 in 2000 to 2,872,372 in 2005. A total of 43,017 new fractures were identified. There was a significant increasing trend in age-adjusted rates of radius and ulna, vertebra, ribs, hip, pelvis, multiple, and pathologic fractures during the period from 2003 through 2005 (P < 0.03). The incidence of each fracture type was significantly greater during 2004 to 2005 than 2000 to 2001 (P < 0.04). The use of estrogen, estrogen plus progestin, and other hormones declined over the period from 2000 to 2003, whereas the use of other bone-modifying drugs increased from 2003 through 2005. CONCLUSIONS The incidence of fractures among perimenopausal and postmenopausal women increased significantly in the 3 years after publication of Women's Health Initiative and Heart and Estrogen/Progestin Replacement Study II results. This trend followed a decline in the use of hormone therapy, concurrent with an increase in the use of other bone-modifying agents.
Collapse
|
22
|
Abstract
Bazedoxifene is a third-generation selective estrogen-receptor modulator being developed for use alone or in combination with estrogen for prevention and treatment of osteoporosis in postmenopausal women. Preliminary clinical trials are encouraging. Bazedoxifene has been found to be efficacious in reducing bone turnover without adverse effects of breast pain. In Phase III studies, bazedoxifene was found to increase vasomotor symptoms when compared with placebo. This effect is similar to that of raloxifene. Lack of endometrial stimulation is another advantage. Current literature suggests that bazedoxifene is likely to be safe, well tolerated and effective for the treatment of postmenopausal osteoporosis. However, completion of Phase III clinical trials will further elucidate its safety and efficacy, as well as its advantages in comparison with other selective estrogen-receptor modulators.
Collapse
Affiliation(s)
- Mohamed Fm Mitwally
- University of New Mexico, Division of Reproductive Endocrinology & Infertility, Department of Obstetrics & Gynecology, Albuquerque, New Mexico, USA.
| |
Collapse
|
23
|
Lewiecki EM. Denosumab in postmenopausal osteoporosis: what the clinician needs to know. Ther Adv Musculoskelet Dis 2009; 1:13-26. [PMID: 22870424 PMCID: PMC3382669 DOI: 10.1177/1759720x09343221] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Denosumab is a subcutaneously (SC) administered investigational fully human monoclonal antibody to receptor activator of nuclear factor-kB ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the principal mediator of osteoclastic bone resorption. RANKL stimulates the formation, activity, and survival of osteoclasts, and is implicated in the pathogenesis of postmenopausal osteoporosis and other skeletal disorders associated with increased bone remodeling. Denosumab binds RANKL, preventing it from binding to RANK, thereby reducing the formation, activity, and survival of osteoclasts and slowing the rate of bone resorption. Postmenopausal women with low bone mineral density (BMD) treated with denosumab have a reduction of bone turnover markers and an increase in BMD that is rapid, sustained, and reversible. In postmenopausal women with osteoporosis, denosumab reduces the risk of vertebral, hip, and nonvertebral fractures. In postmenopausal women with low BMD randomized to receive denosumab or alendronate, denosumab is associated with a significantly greater increase in BMD and further reduction in bone turnover markers compared with alendronate. In postmenopausal women with low BMD who were previously treated with alendronate, those who switched to denosumab have a significantly greater BMD increase and further reduction in bone turnover markers compared with those continuing alendronate. Denosumab is well tolerated with a favorable safety profile. It is a promising emerging drug for the prevention and treatment of osteoporosis, offering a long dosing interval of every 6 months and convenient SC dosing, with the potential of improving long-term adherence to therapy compared with current oral treatments.
Collapse
Affiliation(s)
- E. Michael Lewiecki
- New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM 87106, USA.
| |
Collapse
|
24
|
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008; 15:584-602. [PMID: 18580541 DOI: 10.1097/gme.0b013e31817b076a] [Citation(s) in RCA: 124] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
OBJECTIVE : To update for both clinicians and the lay public the evidence-based position statement published by The North American Menopause Society (NAMS) in March 2007 regarding its recommendations for menopausal hormone therapy (HT) for postmenopausal women, with consideration for the therapeutic benefit-risk ratio at various times through menopause and beyond. DESIGN : An Advisory Panel of clinicians and researchers expert in the field of women's health was enlisted to review the March 2007 NAMS position statement, evaluate new evidence through an evidence-based analysis, and reach consensus on recommendations. The Panel's recommendations were reviewed and approved by the NAMS Board of Trustees as an official NAMS position statement. The document was provided to other interested organizations to seek their endorsement. RESULTS : Current evidence supports a consensus regarding the role of HT in postmenopausal women, when potential therapeutic benefits and risks around the time of menopause are considered. This paper lists all these areas along with explanatory comments. Conclusions that vary from the 2007 position statement are highlighted. Addenda include a discussion of risk concepts, a new component not included in the 2007 paper, and a recommended list of areas for future HT research. A suggested reading list of key references is also provided. CONCLUSIONS : Recent data support the initiation of HT around the time of menopause to treat menopause-related symptoms; to treat or reduce the risk of certain disorders, such as osteoporosis or fractures in select postmenopausal women; or both. The benefit-risk ratio for menopausal HT is favorable close to menopause but decreases with aging and with time since menopause in previously untreated women.
Collapse
|
25
|
Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43:222-229. [PMID: 18539106 DOI: 10.1016/j.bone.2008.04.007] [Citation(s) in RCA: 390] [Impact Index Per Article: 24.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2008] [Revised: 04/01/2008] [Accepted: 04/08/2008] [Indexed: 10/22/2022]
Abstract
INTRODUCTION Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor-kappa B ligand (RANKL), an essential mediator of osteoclast formation, function, and survival that has been shown to decrease bone turnover and increase bone mineral density (BMD) in treated patients. We assessed the long-term efficacy and safety of denosumab, and the effects of discontinuing and restarting denosumab treatment in postmenopausal women with low bone mass. METHODS Postmenopausal women with a lumbar spine T-score of -1.8 to -4.0 or proximal femur T-score of -1.8 to -3.5 were randomized to denosumab every 3 months (Q3M; 6, 14, or 30 mg) or every 6 months (Q6M; 14, 60, 100, or 210 mg); placebo; or open-label oral alendronate weekly. After 24 months, patients receiving denosumab either continued treatment at 60 mg Q6M for an additional 24 months, discontinued therapy, or discontinued treatment for 12 months then re-initiated denosumab (60 mg Q6M) for 12 months. The placebo cohort was maintained. Alendronate-treated patients discontinued alendronate and were followed. Changes in BMD and bone turnover markers (BTM) as well as safety outcomes were evaluated. RESULTS Overall, 262/412 (64%) patients completed 48 months of study. Continuous, long-term denosumab treatment increased BMD at the lumbar spine (9.4% to 11.8%) and total hip (4.0% to 6.1%). BTM were consistently suppressed over 48 months. Discontinuation of denosumab was associated with a BMD decrease of 6.6% at the lumbar spine and 5.3% at the total hip within the first 12 months of treatment discontinuation. Retreatment with denosumab increased lumbar spine BMD by 9.0% from original baseline values. Levels of BTM increased upon discontinuation and decreased with retreatment. Adverse event rates were similar among treatment groups. CONCLUSIONS In postmenopausal women with low BMD, long-term denosumab treatment led to gains in BMD and reduction of BTM throughout the course of the study. The effects on bone turnover were fully reversible with discontinuation and restored with subsequent retreatment.
Collapse
Affiliation(s)
- Paul D Miller
- Colorado Center for Bone Research, 3190 South Wadsworth Blvd, Ste 250, Lakewood, CO 80227, USA.
| | | | - E Michael Lewiecki
- New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
| | | | | | | | - Yu Liu
- Amgen Inc., Thousand Oaks, CA, USA
| | | |
Collapse
|
26
|
Sare GM, Gray LJ, Bath PMW. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008; 29:2031-41. [PMID: 18599555 PMCID: PMC2515884 DOI: 10.1093/eurheartj/ehn299] [Citation(s) in RCA: 125] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
AIMS Randomized controlled trials (RCTs) have shown that the risk of stroke and venous thromboembolism (VTE) is increased with hormone replacement therapy (HRT); the effect on coronary heart disease (CHD) remains unclear. METHODS AND RESULTS RCTs of HRT were identified. Event rates for cerebrovascular disease [stroke, TIA (transient ischaemic attack)], CHD (myocardial infarction, unstable angina, sudden cardiac death), and VTE (pulmonary embolism, deep vein thrombosis) were analysed. Sensitivity analyses were performed by type of HRT (mono vs. dual) and subject age. 31 trials (44 113 subjects) were identified. HRT was associated with increases in stroke (odds ratio, OR, 1.32, 95% confidence intervals, CI, 1.14-1.53) and VTE (OR 2.05, 95% CI 1.44-2.92). In contrast, CHD events were not increased (OR 1.02, 95% CI 0.90-1.11). Ordinal analyses confirmed that stroke severity was increased with HRT (OR 1.31, 95% CI 1.12-1.54). Although most trials included older subjects, age did not significantly affect risk. The addition of progesterone to oestrogen doubled the risk of VTE. CONCLUSION HRT is associated with an increased risk of stroke, stroke severity, and VTE, but not of CHD events. Although most trials studied older patients, increased risk was not related to age. Combined HRT increases the risk of VTE compared with oestrogen monotherapy.
Collapse
Affiliation(s)
- Gillian M Sare
- Stroke Trials Unit, Institute of Neuroscience, University of Nottingham, Nottingham, UK
| | | | | |
Collapse
|
27
|
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008; 23:525-35. [PMID: 18072873 DOI: 10.1359/jbmr.071206] [Citation(s) in RCA: 179] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
UNLABELLED Osteoporosis is an increasingly common health concern in postmenopausal women. In a 2-yr phase III study, bazedoxifene prevented bone loss, reduced bone turnover, and was well tolerated in early postmenopausal women with normal or low BMD. INTRODUCTION Bazedoxifene is a novel selective estrogen receptor modulator that has increased BMD and bone strength in experimental models, without stimulating breast or uterus. This 24-mo, randomized, double-blind study assessed the efficacy and safety of three doses of bazedoxifene compared with placebo and raloxifene in the prevention of postmenopausal osteoporosis. MATERIALS AND METHODS Healthy postmenopausal women with a BMD T-score at the lumbar spine or femoral neck between -1.0 and -2.5 or clinical risk factors for osteoporosis were randomly assigned to one of five groups: bazedoxifene 10, 20, or 40 mg/d, placebo, or raloxifene 60 mg/d. All women received elemental calcium. Efficacy outcomes included changes from baseline through 24 mo in BMD of the lumbar spine, hip, femoral neck, and femoral trochanter and biomarkers of bone metabolism. RESULTS The intent-to-treat population included 1434 women (mean age, 58 yr; mean time from last menstrual period, 11 yr). All doses of bazedoxifene and raloxifene prevented bone loss, whereas in the placebo group, there was significant loss of BMD at all skeletal sites. Mean differences in percent change in lumbar spine BMD from baseline to 24 mo relative to placebo were 1.08 +/- 0.28%, 1.41 +/- 0.28%, 1.49 +/- 0.28%, and 1.49 +/- 0.28% for 10, 20, and 40 mg bazedoxifene and 60 mg raloxifene, respectively (p < 0.001 for all comparisons). Comparable BMD responses were observed at other body sites. Significant and comparable decreases in serum osteocalcin and C-telopeptide levels from baseline and relative to placebo with active treatment were observed as early as 3 mo and were sustained through study conclusion (p < 0.001). Overall incidences of adverse events, serious adverse events, and discontinuations caused by adverse events were similar between groups. The most common adverse events included headache, infection, arthralgia, pain, hot flush, and back pain. CONCLUSIONS Treatment with bazedoxifene prevented bone loss and reduced bone turnover equally as well as raloxifene and was generally well tolerated in postmenopausal women with normal/low BMD.
Collapse
|
28
|
Brandão CMR, Lima MG, Silva ALD, Silva GD, Guerra Jr. AA, Acúrcio FDA. Treatment of postmenopausal osteoporosis in women: a systematic review. CAD SAUDE PUBLICA 2008; 24 Suppl 4:s592-606. [DOI: 10.1590/s0102-311x2008001600011] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2008] [Accepted: 03/25/2008] [Indexed: 11/21/2022] Open
Abstract
Osteoporosis, a typical disease of the elderly, has become a frequent and relevant public health problem. Several drugs are available for treatment of osteoporosis, some of which are currently dispensed by the Brazilian Unified National Health System. The objective of this study was to present a systematic review of drugs for treatment of osteoporosis, focusing on the adequacy of clinical protocols based on existing evidence in the scientific literature. We conducted a search for randomized clinical trials in PubMed and LILACS that presented results for bone mineral density, incidence of vertebral fractures, and adverse effects. 32 articles met the review's inclusion criteria. Bisphosphonates were reported to have consistently reduced the risk of vertebral fractures. Hormone replacement therapy showed positive outcomes, but its use has been found to increase the risk of cardiovascular disease and breast cancer. Teriparatide and monofluorophosphate also showed efficacy against osteoporosis. Calcium and vitamin D were given to patients as food supplements.
Collapse
|
29
|
|
30
|
Rozenfeld S. [Hormone therapy and menopause (HT): multiple interests to consider]. CIENCIA & SAUDE COLETIVA 2007; 12:437-42. [PMID: 17680099 DOI: 10.1590/s1413-81232007000200020] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2005] [Accepted: 01/25/2006] [Indexed: 11/22/2022] Open
Abstract
In 2002, the Women's Health Initiative (WHI) study was interrupted as evidence indicated that the use of hormones increased the risk of cardiovascular disease and of breast cancer. Since then scientific literature has pointed to three nuclei of interest for that issue: women, the doctor and the pharmaceutical industry. Regarding women, the following issues are emphasized: the cultural aspects of menopause, the feminist movements' struggle and the absence of enough epidemiological studies. With respect to doctors the lack of information on the safety of drugs is an important topic. Regarding the pharmaceutical industry the prevailing motivation is their economic interests.
Collapse
Affiliation(s)
- Suely Rozenfeld
- Departamento de Epidemiologia, Escola Nacional de Saúde Pública, Fiocruz, Rio de Janeiro.
| |
Collapse
|
31
|
Abstract
BACKGROUND In the absence of unmeasured confounding, standard methods for estimating the effects of time-varying treatments on an event are biased when a time-dependent risk factor for the event also predicts subsequent treatments and when past treatment history predicts subsequent risk factor levels. In contrast, structural models provide unbiased estimates of effects when unmeasured confounding is absent. METHODS We describe a multiplicative structural mean model and use it to estimate the effects of time-varying osteoporosis treatments on incidence of fractures among 1328 postmenopausal women over 40 years of age in a hospital-based cohort study in Japan. The parameters of the structural mean model are estimated by g-estimation. RESULTS The number of vertebral fractures and bone mineral density levels predicted the selection of subsequent treatments and were affected by the previous treatments. Incidence rate ratios of bisphosphonates, active vitamin D3, and conjugated estrogen compared with no drug therapy were 0.58 (95% confidence interval = 0.44-0.77), 0.82 (0.48-1.38), and 0.60 (0.47-0.76), respectively, after adjusting time-dependent confounders. For initial treatments estimated by the standard Poisson-GEE, incidence rate ratios were 1.61 (1.23-2.10), 1.16 (0.96-1.40), and 0.73 (0.52-1.02), respectively. CONCLUSIONS Our analysis using the structural mean model showed that bisphosphonates, active vitamin D3, and conjugated estrogen all had preventive effects on the incidence of fractures by appropriate adjustments for time-dependent confounders. The results from standard Poisson-GEE analysis were the opposite of these results and of evidence from randomized trials. We consider our methods useful to estimate time-varying treatments within observational data.
Collapse
Affiliation(s)
- Shiro Tanaka
- Department of Biostatistics/Epidemiology and Preventive Health Sciences, School of Health Sciences and Nursing, University of Tokyo, Tokyo, Japan.
| | | | | | | |
Collapse
|
32
|
Chen YT, Miller PD, Barrett-Connor E, Weiss TW, Sajjan SG, Siris ES. An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture. Osteoporos Int 2007; 18:1287-96. [PMID: 17464525 DOI: 10.1007/s00198-007-0380-6] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/11/2006] [Accepted: 02/27/2007] [Indexed: 10/23/2022]
Abstract
UNLABELLED Using data from NORA, we used 18 potential risk factors in a classification and regression tree analysis to build two algorithms. These algorithms correctly identified postmenopausal women between the ages of 50 and 64 years who were at the highest risk of osteoporotic fracture within 36 months. INTRODUCTION The objective was to develop algorithms that best predict short-term fracture risk (3 years) in postmenopausal women 50-64 years old. METHODS Data were from 91,652 women who responded to follow-up surveys as part of National Osteoporosis Risk Assessment (NORA) study. Peripheral bone mineral density (BMD) and risk factors obtained at baseline; incident osteoporotic fractures obtained from follow-up surveys. Eighteen risk factors were entered into a classification and regression tree analysis to build two algorithms, one with and one without BMD. RESULTS Two thousand and seven (2.2%) women reported new osteoporotic fractures. Prior fracture, a peripheral BMD T-score <or= -1.1, and self-reported fair/poor health status were the most important determinants for short-term fracture and were associated, respectively, with 7.2%, 3.1%, and 2.4% fracture risk within 3 years. This algorithm with three risk factors correctly classified 65% of the women who experienced an incident fracture and 59% of the women who did not experience an incident fracture. Without BMD T-score, the most important determinants for fracture prediction were previous fracture, self-reported fair/poor health status, and no current use of postmenopausal hormone therapy. CONCLUSIONS NORA-based algorithms may be useful for health care providers to guide further assessment and management decisions to prevent fractures in younger postmenopausal women.
Collapse
Affiliation(s)
- Y-T Chen
- Department of Outcomes Research and Management, Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA 19486, USA.
| | | | | | | | | | | |
Collapse
|
33
|
Affiliation(s)
- Nico C Geurs
- Department of Periodontology, School of Dentistry, University of Alabama at Birmingham, USA
| |
Collapse
|
34
|
Tolea MI, Black SA, Carter-Pokras OD, Kling MA. Depressive symptoms as a risk factor for osteoporosis and fractures in older Mexican American women. Osteoporos Int 2007; 18:315-22. [PMID: 17053870 DOI: 10.1007/s00198-006-0242-7] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2006] [Accepted: 09/22/2006] [Indexed: 10/24/2022]
Abstract
INTRODUCTION AND HYPOTHESIS Despite higher rates of depression, lower hormone replacement therapy (HRT) use, and inadequate knowledge of factors associated with osteoporosis, Mexican Americans have been understudied with regards to the association between depression, osteoporosis, and fractures. We hypothesized that depression increases the risk for osteoporosis and fractures among older Mexican American women. METHODS Seven years of prospective data (1993-2001) from the Hispanic Established Populations for Epidemiologic Studies of the Elderly were analyzed for 1,350 women in the Southwest United States who had complete data for at least the first follow-up interview. RESULTS Respondents (mean age:75) were generally poorly educated, had low income, and reported poor or fair health. High levels of depressive symptoms were reported by 31%, while new diagnosis of osteoporosis and new fractures were reported by 18 and 13%, respectively. Logistic regression analyses showed that predictors of newly diagnosed osteoporosis included age, high school (HS) education, ever having been an alcoholic, early menopause, hormone replacement therapy, and high levels of depressive symptoms. Factors predictive of new fractures included age, HS education, diabetes, early menopause, and high levels of depressive symptoms. CONCLUSIONS Depressive symptoms were associated with increased risk of osteoporosis and new fractures, even after controlling for other predictive factors.
Collapse
Affiliation(s)
- M I Tolea
- Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Howard Hall room 140C, 660 West Redwood Street, Baltimore, MD 21201, USA.
| | | | | | | |
Collapse
|
35
|
Abstract
OBJECTIVE To update the evidence-based position statement published by The North American Menopause Society (NAMS) in 2002 regarding the management of osteoporosis in postmenopausal women. DESIGN NAMS followed the general principles established for evidence-based guidelines to create this updated document. A panel of clinicians and researchers expert in the field of metabolic bone diseases and/or women's health were enlisted to review the 2002 NAMS position statement, compile supporting statements, and reach consensus on recommendations. The panel's recommendations were reviewed and approved by the NAMS Board of Trustees. RESULTS Osteoporosis, whose prevalence is especially high among elderly postmenopausal women, increases the risk of fractures. Hip and spine fractures are associated with particularly high morbidity and mortality in this population. Given the health implications of osteoporotic fractures, the primary goal of osteoporosis therapy is to prevent fractures, which is accomplished by slowing or stopping bone loss, maintaining bone strength, and minimizing or eliminating factors that may contribute to fractures. The evaluation of postmenopausal women for osteoporosis risk requires a medical history, physical examination, and diagnostic tests. Major risk factors for postmenopausal osteoporosis (as defined by bone mineral density) include advanced age, genetics, lifestyle factors (such as low calcium and vitamin D intake, smoking), thinness, and menopause status. The most common risk factors for osteoporotic fracture are advanced age, low bone mineral density, and previous fracture as an adult. Management focuses first on nonpharmacologic measures, such as a balanced diet, adequate calcium and vitamin D intake, adequate exercise, smoking cessation, avoidance of excessive alcohol intake, and fall prevention. If pharmacologic therapy is indicated, government-approved options are bisphosphonates, a selective estrogen-receptor modulator, parathyroid hormone, estrogens, and calcitonin. CONCLUSIONS Management strategies for postmenopausal women involve identifying those at risk of low bone density and fracture, followed by instituting measures that focus on reducing modifiable risk factors through lifestyle changes and, if indicated, pharmacologic therapy.
Collapse
|
36
|
Abstract
HRT has been widely used for the relief of menopausal symptoms and the prevention and treatment of post-menopausal osteoporosis. However, following the publication of the Women's Health Initiative (WHI) and the Million Women Study (MWS), regulatory authorities issued an urgent safety restriction on HRT use in preventing post-menopausal osteoporosis, recommending that it now be considered a second-line treatment. Are such recommendations justified? Treatments for osteoporosis, in women with increased future risk for fractures but who have not yet developed the disease, should prevent all types of osteoporotic fractures. Of the available therapies, none other than HRT has been clearly demonstrated to prevent hip fractures in such women. Thus, HRT should be recommended as first-line treatment for osteoporosis prevention. Potential risks of HRT, such as increased development of breast cancer and increased thromboembolism, have long been known. The WHI showed risks in less than 0.3% of women studied, and the MWS appears to have overestimated the risk of breast cancer. Thus, no new safety issues have been identified, and the regulatory authorities may have misinterpreted the data from these recent studies. When given for the correct indications, HRT is of major benefit to many women.
Collapse
Affiliation(s)
- John C Stevenson
- National Heart & Lung Division, Faculty of Medicine, Imperial College London, Royal Brompton Hospital, UK.
| |
Collapse
|
37
|
Sánchez-Mariscal D, Bailón-Muñoz E. [Attitude to a post-menopausal woman who consults due to flushes and dyspareunia]. Aten Primaria 2006; 37:167-72. [PMID: 16527139 PMCID: PMC7668917 DOI: 10.1157/13085351] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2004] [Accepted: 01/10/2005] [Indexed: 11/21/2022] Open
Affiliation(s)
| | - E. Bailón-Muñoz
- Unidad Docente de Medicina Familiar y Comunitaria. Granada. España
| |
Collapse
|
38
|
Delaney MF. Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol 2006; 194:S12-23. [PMID: 16448872 DOI: 10.1016/j.ajog.2005.08.049] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2005] [Accepted: 08/18/2005] [Indexed: 12/26/2022]
Abstract
During the perimenopause, both the quantity and quality of bone decline rapidly, resulting in a dramatic increase in the risk of fracture in postmenopausal women. Although many factors are known to be associated with osteoporotic fractures, measures to identify and treat women at risk are underused in clinical practice. Consequently, osteoporosis is frequently not detected until a fracture occurs. Identification of postmenopausal women at high risk of fracture therefore is a priority and is especially important for women in early postmenopause who can benefit from early intervention to maintain or to increase bone mass and, thus, reduce the risk of fracture. Most authorities recommend risk-factor assessment for all postmenopausal women, followed by bone mineral density measurements for women at highest risk (ie, all women aged > or =65 years, postmenopausal women aged <65 years with > or =1 additional risk factors for osteoporosis, and postmenopausal women with fragility fractures). All postmenopausal women can benefit from nonpharmacologic interventions to reduce the risk of fracture, including a balanced diet with adequate intake of calcium and vitamin D, regular exercise, measures to prevent falls or to minimize their impact, smoking cessation, and moderation of alcohol intake. Several pharmacologic agents, including the bisphosphonates (eg, alendronate, risedronate, and ibandronate) and the selective estrogen receptor modulator, raloxifene, have been shown to increase bone mass, to reduce fracture risk, and to have acceptable side-effect profiles. Women who have discontinued hormone therapy are in particular need of monitoring for fracture risk, in light of the accelerated bone loss and increased risk of fracture that occurs after withdrawal of estrogen treatment.
Collapse
Affiliation(s)
- Miriam F Delaney
- Center for Osteoporosis and Metabolic Bone Diseases, Rheumatology Division, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
| |
Collapse
|
39
|
Thorpe DL, Knutsen SF, Beeson WL, Fraser GE. The effect of vigorous physical activity and risk of wrist fracture over 25 years in a low-risk survivor cohort. J Bone Miner Metab 2006; 24:476-83. [PMID: 17072740 DOI: 10.1007/s00774-006-0715-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2006] [Accepted: 06/30/2006] [Indexed: 10/24/2022]
Abstract
Recent studies have suggested that a high level of recent physical activity increases the risk of a wrist fracture in postmenopausal women. The relationship of more distant past physical activity to wrist fracture is less clear, and most studies have relied on recall of physical activity much earlier in life. The aim of this study was to assess the risk of wrist fracture in a subset of women who had completed a recent questionnaire and also had participated in a cohort study 25 years earlier, 1865 women who were perimenopausal and postmenopausal in 1976 and had completed the 1976 and 2002 Adventist Health Study lifestyle questionnaires. Data on risk factors including physical activity were collected from the 1976 survey. Subjects reported wrist fractures occurring since baseline, and the approximate time of fracture, in the 2002 questionnaire. Incidence of wrist fracture was 3.7/1000 person-years of follow up. There was a dose-response inverse relationship between level of physical activity and wrist fracture with a 37% reduction of risk for the highest level of physical activity with respect to the lowest level (HR, 0.63; 95% CI, 0.45, 0.89). The effect of physical activity changed little in the final multivariable model (HR, 0.61; 95% CI, 0.43, 0.87). In this cohort of women with a relatively low incidence of wrist fracture, higher levels of physical activity at baseline were protective against risk of fracture during 25 years of follow-up.
Collapse
Affiliation(s)
- Donna L Thorpe
- Department of Physical Therapy, School of Allied Health Professions, Loma Linda University, Loma Linda, CA 92350, USA.
| | | | | | | |
Collapse
|
40
|
Cussler EC, Going SB, Houtkooper LB, Stanford VA, Blew RM, Flint-Wagner HG, Metcalfe LL, Choi JE, Lohman TG. Exercise frequency and calcium intake predict 4-year bone changes in postmenopausal women. Osteoporos Int 2005; 16:2129-41. [PMID: 16283062 DOI: 10.1007/s00198-005-2014-1] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2005] [Accepted: 08/11/2005] [Indexed: 01/02/2023]
Abstract
The aim of this study was to examine the association of exercise frequency and calcium intake (CI) with change in regional and total bone mineral density (BMD) in a group of postmenopausal women completing 4 years of progressive strength training. One hundred sixty-seven calcium-supplemented (800 mg/day) sedentary women (56.1+/-4.5 years) randomized to a progressive strength training exercise program or to control were followed for 4 years. Fifty-four percent of the women were using hormone therapy (HT) at baseline. At 1 year, controls were permitted to begin the exercise program (crossovers). The final sample included 23 controls, 55 crossovers, and 89 randomized exercisers. Exercisers were instructed to complete two sets of six to eight repetitions of exercises at 70-80% of one repetition maximum, three times weekly. BMD was measured at baseline and thereafter annually using dual-energy X-ray absorptiometry. Four-year percentage exercise frequency (ExFreq) averaged 26.8%+/-20.1% for crossovers (including the first year at 0%), and 50.4%+/-26.7% for exercisers. Four-year total CI averaged 1,635+/-367 mg/day and supplemental calcium intake, 711+/-174 mg/day. In adjusted multiple linear regression models, ExFreq was positively and significantly related to changes in femur trochanter (FT) and neck (FN), lumbar spine (LS), and total body (TB) BMD. Among HT users, FT BMD increased 1.5%, and FN and LS BMD, 1.2% (p<0.01) for each standard deviation (SD) of percentage ExFreq (29.5% or 0.9 days/week). HT non-users gained 1.9% and 2.3% BMD at FT and FN, respectively, (p<0.05) for every SD of CI. The significant, positive, association between BMD change and ExFreq supports the long-term usefulness of strength training exercise for the prevention of osteoporosis in postmenopausal women, especially HT users. The positive relationship of CI to change in BMD among postmenopausal women not using HT has clinical implications in light of recent evidence of an increased health risk associated with HT.
Collapse
Affiliation(s)
- Ellen C Cussler
- Department of Physiology, University of Arizona, Tucson, AZ, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
Major advancements in the treatment of osteoporosis have occurred over the last decade. Therapies including the anti-resorptive drugs such as alendronate and risedronate have been shown in randomized placebo-controlled trials to increase bone mineral density and reduce fracture risk. Anabolic therapy in the form of parathyroid hormone has been introduced as the first treatment to build bone mass. However, gaps in our knowledge about specific management issues that arise frequently among primary care providers persist. In this paper, three common clinical scenarios are discussed: a postmenopausal woman with only slightly reduced bone mineral density; an osteoporotic woman on anti-resorptive therapy for more than 5 years; and a woman who continues to fracture despite treatment. Evidence gaps in each treatment scenario are presented, and rational approaches to management are suggested.
Collapse
Affiliation(s)
- Clifford J Rosen
- Maine Center for Osteoporosis Research and Education, St. Joseph Hospital, Bangor, Me 04401, USA.
| | | |
Collapse
|
42
|
Paganini-Hill A, Atchison KA, Gornbein JA, Nattiv A, Service SK, White SC. Menstrual and Reproductive Factors and Fracture Risk: The Leisure World Cohort Study. J Womens Health (Larchmt) 2005; 14:808-19. [PMID: 16313208 DOI: 10.1089/jwh.2005.14.808] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Because menopausal estrogen is related to the development of osteoporosis, we investigated the potential associations of the estrogen-related events of menarche, pregnancy, and menopause with fracture risk in a population-based, prospective study of older women. METHODS The Leisure World Cohort was established in the early 1980s when residents of a California retirement community, including 8877 women, completed a health survey. Incident fractures of the hip (n = 1220), wrist (n = 463), and spine (n = 613) incurred over two decades were identified from four follow-up questionnaires, hospital discharge records, and (for hip fracture) death certificates. Hazard ratios (HR) adjusted for age and other potential confounders were calculated using proportional hazards regression. RESULTS Late age at menarche was associated with decreased hip fracture risk (HR = 0.84, 95% CI 0.72-0.98, for age > or = 14 vs. < or = 12 years) but was unrelated to fractures at other sites. Hip fracture risk was also reduced in women who had been pregnant (HR = 0.83, 95% CI 0.72- 0.95). Women who reported menopause at age 45+ had a lower risk of wrist fracture compared with those with menopause at age < or = 44 (HR = 0.74, 95% CI 0.58-0.95 for ages 45-54; HR = 0.71, 95% CI 0.49-1.04 for ages 55+). Although fracture risks did not differ between ever and never users of menopausal estrogen, recency since last use was related to wrist fractures (HR = 1.09, 95% CI 1.03-1.16 for each 5 years since last years). CONCLUSIONS The estrogen-related events of menarche, pregnancy, and menopause were not associated with osteoporotic fracture risk in a consistent manner. Other factors related to these events may be influencing development of osteoporosis and the likelihood of sustaining a fracture in older women.
Collapse
Affiliation(s)
- Annlia Paganini-Hill
- Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
| | | | | | | | | | | |
Collapse
|
43
|
Abstract
The progressive loss of bone mass that leads to osteoporosis in postmenopausal women is known to result in substantial morbidity and mortality. Underdiagnosed and undertreated, osteoporosis jeopardizes the health of an estimated 8 million American women 50 years of age or older who are at high risk for hip, vertebral, and other fractures. Because osteopenia is generally a subclinical condition that results in a lower fracture rate than osteoporosis, its potential impact is more difficult to recognize, although it is nearly three times more prevalent than osteoporosis. The question arises as to whether osteopenia should be diagnosed and treated before it transitions into osteoporosis. Because the number of postmenopausal women is projected to increase substantially in the near future and the number of postmenopausal women who will or who have discontinued their use of hormone therapy has increased sharply, the consequences of failing to identify and treat women at increased fracture risk are considerable. Moreover, the rate of bone loss in the first year after discontinuation of hormone therapy is especially rapid and similar to the rate that occurs early after menopause. Accordingly, fracture risk is substantially increased at this time in relation to the magnitude of bone loss. The goal of nonpharmacologic and pharmacologic therapy is to prevent the first fracture in any woman at risk for fracture. Initiation of antiresorptive therapy known to provide rapid efficacy can be particularly important in achieving the treatment goal in appropriate osteopenic women.
Collapse
Affiliation(s)
- James A Simon
- George Washington University School of Medicine, Washington, DC 20036-5803, USA.
| |
Collapse
|
44
|
Rolnick SJ, Kopher RA, DeFor TA, Kelley ME. Hormone use and patient concerns after the findings of the Women's Health Initiative. Menopause 2005; 12:399-404. [PMID: 16037754 DOI: 10.1097/01.gme.0000148644.55486.36] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2004] [Revised: 11/02/2004] [Accepted: 11/02/2004] [Indexed: 12/28/2022]
Abstract
OBJECTIVE To assess behaviors and concerns related to hormone therapy after the findings of the Women's Health Initiative (WHI). DESIGN A survey was mailed to a random sample of 1,200 women identified through the pharmacy database as taking one of two estrogen + progestogen therapies (EPT) during the 6-month period before the publication of WHI findings. Questions included hormone use history, changes in usage, an assessment of symptoms, symptom changes, health behavior changes, use of alternative therapies, and demographics. RESULTS The response rate was 70%, with women in their 60s and those receiving hormone therapy for 5 or more years were more likely to respond (P < 0.05). The majority had started hormones for symptom relief (69%) and expected to continue use. Many reported discontinuation (63%) or modifying their medication (18%). Half of these women stopped then restarted, the other half changed products. Women in their 50s were more likely to remain on hormones than older women (P < 0.01), and those taking ethinyl estradiol and norethindrone acetate were more likely to remain on their medication than those on conjugated estrogens (43% vs 29%, P < 0.01). Little change was reported in exercise and 19% increased their calcium intake. Patient concerns fell into five major categories: long-term effects, symptom control, breast cancer risk, bone health, and cognitive function. CONCLUSIONS Women seem to be heeding the warnings about hormones but remain concerned about the potential long-term sequelae and symptom control. More research is needed to identify safer approaches to symptom relief and to address the concerns expressed.
Collapse
Affiliation(s)
- Sharon J Rolnick
- HealthPartners Research Foundation, Minneapolis, MN 55440-1524, USA.
| | | | | | | |
Collapse
|
45
|
Abstract
Clinical trials show that hormone therapy (HT) is an effective treatment for vasomotor symptoms and vaginal dryness. HT improves other symptoms including sleep and quality of life in women who have menopause symptoms. In the Women's Health Initiative controlled clinical trials, both estrogen therapy (ET) and estrogen plus progestin therapy (EPT) reduced fracture risk, neither reduced the risk of heart disease, and both increased the risk of stroke, deep vein thrombosis, and dementia. EPT, but not ET, increased breast cancer risk and reduced colon cancer risk. Differences between EPT and ET may reflect chance, baseline differences between the EPT and ET cohorts, or a progestin effect. Studies of younger women and lower HT doses with intermediate endpoints are beginning.
Collapse
Affiliation(s)
- Elizabeth Barrett-Connor
- Division of Epidemiology, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, 92093-0607, USA.
| | | | | |
Collapse
|
46
|
Tamborini A, Ruiz JC. [Current role of hormone replacement therapy in the prevention of postmenopausal osteoporosis: gynecologic point of view]. Rev Med Interne 2005; 25 Suppl 5:S580-7. [PMID: 15841951 DOI: 10.1016/s0248-8663(04)80058-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Hormonal Replacement Therapy (HRT) of the menopause has already proved to be effective in preventing bone loss and reducing the risk of fractures in postmenopausal women. Up until 2002, HRT was widely proposed and prescribed by French practitioners, in particular with regard to the prevention of osteoporosis. The results of two major studies, one American, the Women's Health Initiative (WHI) Study, and the other British, the Million Women Study (MWS), published in July 2002 and August 2003, have called into question the hitherto favourable benefits/risks ratio of HRT after finding an increased incidence of breast cancer and heart disease amongst women undergoing this treatment. Following these studies, the European and French health authorities have issued new recommendations regulating and restricting the use of HRT with a drastic restriction on the indications for its use in the prevention of osteoporosis. These new recommendations are the subject of controversy and pose new problems for practitioners.
Collapse
Affiliation(s)
- A Tamborini
- Centre de surveillance et traitement de la ménopause, service de gynécologie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
| | | |
Collapse
|
47
|
Szymanski LM, Kessler CM, Fernhall B. Relationship of physical fitness, hormone replacement therapy, and hemostatic risk factors in postmenopausal women. J Appl Physiol (1985) 2005; 98:1341-8. [PMID: 15591298 DOI: 10.1152/japplphysiol.00622.2004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
This cross-sectional study evaluated the relationship of physical fitness, hormone replacement therapy (HRT), and hemostatic profiles at rest and after an acute bout of maximal exercise in 48 healthy postmenopausal women. Subjects were categorized by fitness and HRT user status into four groups: unfit nonusers, fit nonusers, unfit users, and fit users. Fibrinolytic variables tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) activity, and antigen and prothrombin fragment 1 + 2, a molecular marker of in vivo thrombin generation, were measured before and after maximal exercise. Fibrinogen was also measured at rest. Higher tPA and lower PAI-1 activities ( P < 0.05) were seen in HRT users and fit groups. tPA and PAI-1 antigens were lower in HRT and fit groups ( P < 0.05) but not after correction for body mass index. Prothrombin fragment 1 + 2 was lower in the fit groups regardless of HRT status ( P < 0.05). Fibrinogen was similar in all groups. Favorable hemostatic profiles were observed in physically fit compared with unfit women, especially in HRT nonusers. Thus fitness is more strongly related to these hemostatic risk factors compared with HRT since HRT did not affect these hemostatic variables in fit postmenopausal women.
Collapse
Affiliation(s)
- Linda M Szymanski
- College of Applied Life Studies, MC-586, 1206 S. Fourth St., Champaign, IL 61820, USA
| | | | | |
Collapse
|
48
|
Abstract
Hormone replacement therapy prevents bone loss and the increase in bone resorption due to the hormone deficiency in oestrogen in postmenopausal women. The WHI (Women's Health Initiative) randomised, double-blind study against placebo, demonstrated that which all the epidemiological trials had already suggested: replacement therapy can reducing by around 30% the risk of fractures in postmenopausal women. Administration of hormone replacement therapy requires account being taken of (in view of the uncertainties regarding the anti-fracture effect of low dose therapy): the duration (in view of the absence of remnant effect of the product on bone loss and on the risk of fracture) and the benefit/risk ration (in view of the benefits demonstrated on climacteric disorders, but the increase in risk of breast cancer). The menopause is the occasion to assess individual risks, notably vascular and of fractures, taking into account the clinical risk factors and measurement of bone density.
Collapse
Affiliation(s)
- Christian Roux
- Service de rhumatologie, Université René Descartes, Hôpital Cochin, 27, rue du Faubourg, St Jacques, 75014 Paris.
| |
Collapse
|
49
|
Khong S, Savic G, Gardner BP, Ashworth F. Hormone replacement therapy in women with spinal cord injury – a survey with literature review. Spinal Cord 2004; 43:67-73. [PMID: 15570321 DOI: 10.1038/sj.sc.3101694] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
STUDY DESIGN Postal questionnaire survey. OBJECTIVE To examine the current use of hormone replacement therapy (HRT) in a sample of menopausal women with spinal cord injury (SCI). SETTING National Spinal Injuries Centre (NSIC), Stoke Mandeville Hospital, Aylesbury, UK. METHOD A postal questionnaire was sent to 94 women from the NSIC patient database who met the study inclusion criteria (wheelchair dependent, aged 49 years and above, last seen or heard from within the last 3 years). RESULTS A total of 59 valid questionnaires were analysed. At the time of the survey, 50 women were menopausal and 11 of them were using HRT, six for menopausal symptoms and five for osteoporosis prevention. Another 11 had used HRT, eight for menopausal symptoms and three for osteoporosis prevention, but had discontinued it. The main reasons for stopping HRT were side effects. Of the 28 women who had never been on HRT, 20 had either enquired about it, or had been offered HRT, but decided against it. Of the nine women who were still premenopausal at the time of the survey, four would consider using HRT. CONCLUSIONS Results show that 44% of the menopausal women in our sample have used HRT at some point and 22% still do, mostly for treatment of menopausal symptoms and for osteoporosis prevention. In view of the latest literature findings in able-bodied women, use of HRT for osteoporosis prevention in women with SCI may have to be reconsidered.
Collapse
Affiliation(s)
- S Khong
- Department of Obstetrics and Gynaecology, Stoke Mandeville Hospital, Aylesbury, Bucks, UK
| | | | | | | |
Collapse
|
50
|
Yates J, Barrett-Connor E, Barlas S, Chen YT, Miller PD, Siris ES. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 2004; 103:440-6. [PMID: 14990403 DOI: 10.1097/01.aog.0000114986.14806.37] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE Since the findings from the Women's Health Initiative became available in July 2002, millions of women have discontinued postmenopausal hormone therapy (HT). The objective of this study was to evaluate the association between HT cessation and hip fracture risk. METHODS Women who participated in the National Osteoporosis Risk Assessment and completed the 12-month follow-up survey were studied. All participants were aged at least 50 years, were postmenopausal, and had no previous diagnosis of osteoporosis. Baseline and 12-month follow-up questionnaires assessed use of HT and incident fractures. Of the 140,584 women in this study, 269 reported an incident hip fracture. A logistic regression model was used to assess association between HT use and incident hip fracture, controlling for potential confounders. RESULTS Consistent with the Women's Health Initiative, women in National Osteoporosis Risk Assessment who were currently on HT had a 40% lower incidence of hip fractures compared with those who never used HT. Women who stopped using HT more than 5 years earlier had similar hip fracture risk to never users, as expected. However, surprisingly, women who had discontinued HT within the previous 5 years had an increased hip fracture odds ratio of 1.65 (95% confidence interval 1.05, 2.59) relative to never users of HT. CONCLUSION Postmenopausal women who have discontinued HT within the past 5 years have a risk for hip fracture that is at least as high as that in women who have never used HT. LEVEL OF EVIDENCE II-2
Collapse
Affiliation(s)
- John Yates
- Merck and Company, Inc., Upper Gwynedd, Pennsylvania, USA.
| | | | | | | | | | | |
Collapse
|